Point72 Asia Singapore Pte. Ltd. purchased a new stake in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 18,027 shares of the company’s stock, valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.05% of Reneo Pharmaceuticals as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Pale Fire Capital SE raised its holdings in Reneo Pharmaceuticals by 102.7% during the fourth quarter. Pale Fire Capital SE now owns 30,100 shares of the company’s stock valued at $48,000 after buying an additional 15,249 shares in the last quarter. Marquette Asset Management LLC acquired a new position in shares of Reneo Pharmaceuticals during the 1st quarter valued at about $122,000. Vestal Point Capital LP bought a new position in shares of Reneo Pharmaceuticals in the 4th quarter valued at approximately $640,000. Finally, Highbridge Capital Management LLC lifted its holdings in Reneo Pharmaceuticals by 6.5% in the 2nd quarter. Highbridge Capital Management LLC now owns 2,915,376 shares of the company’s stock worth $4,402,000 after purchasing an additional 178,806 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.
Insider Activity
In other Reneo Pharmaceuticals news, major shareholder Braden Michael Leonard acquired 55,300 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average price of $1.36 per share, with a total value of $75,208.00. Following the transaction, the insider now owns 3,358,243 shares of the company’s stock, valued at $4,567,210.48. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have acquired 256,239 shares of company stock valued at $355,105. 17.90% of the stock is owned by insiders.
Reneo Pharmaceuticals Stock Up 0.6 %
Reneo Pharmaceuticals (NASDAQ:RPHM – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. On average, analysts predict that Reneo Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.
About Reneo Pharmaceuticals
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Featured Stories
- Five stocks we like better than Reneo Pharmaceuticals
- How is Compound Interest Calculated?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Conference Calls and Individual Investors
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Following Congress Stock Trades
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.